文献速递呼吸道感染

表面活性蛋白A调控细胞外囊泡内化与降解用于肺部炎症MicroRNA递送

Advanced MicroRNA delivery for lung inflammatory therapy: surfactant protein A controls cellular internalisation and degradation of extracellular vesicles.
PubMed 文献 · Thorax · 2025-04-15

本研究探索SP-A修饰的细胞外囊泡(SP-A-EVs)作为肺部炎症靶向递送系统的生物学意义。研究发现呼吸来源EVs表达SP-A受体SP-R210,SP-A-EVs在体外和体内均被肺泡巨噬细胞高效内化,经TLR4介导的内吞途径摄取并显著延迟降解。加载抗炎microRNA let-7b的SP-A-EVs可抑制AM活化并缓解LPS诱导的肺部炎症。

要点

  • SP-A-EVs经TLR4介导内吞进入肺泡巨噬细胞,降解显著延迟
  • SP-A-EVs加载let-7b可抑制AM活化、缓解LPS诱导肺炎症
  • SP-A与AM强亲和力及内化调控是靶向递送关键

核心结论

  • SP-A-EVs凭借AM与SP-A的强亲和力及对内化途径的调控,可作为肺部疾病靶向治疗的高效药物递送系统。

研究设计与样本

  • 研究验证呼吸来源EVs表达SP-A受体SP-R210以促进SP-A与EVs结合,并在小鼠体内模型评估递送效率、细胞内化途径和治疗效果。

主要发现

  • SP-A-EVs在体外和体内均被AMs稳健内化。
  • SP-A-EVs经TLR4介导的内吞途径摄取,较主要经传统溶酶体降解途径的自然EVs显著延迟降解。
  • 加载抗炎microRNA let-7b的SP-A-EVs抑制AM活化并缓解LPS诱导的肺部炎症。

临床怎么用

  • SP-A-EVs可作为靶向肺泡巨噬细胞的递送平台,用于加载抗炎microRNA治疗肺部炎症性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alveolar macrophages (AMs) are the first line of defence against pathogens that initiate an inflammatory response in the lungs and exhibit a strong affinity for surfactant protein A (SP-A). Extracellular vesicles (EVs) have emerged as a promising drug delivery platform due to their minimal cytotoxicity. However, precise targeting of specific cell types and the rapid lysosomal degradation of EVs within recipient cells remain persistent challenges. METHOD: In this study, we explored the biological significance of SP-A-EVs as novel drug delivery systems for combating lung inflammation. We first verified that respiratory EVs express SP-A receptor (SP-R210), facilitating the conjugation of SP-A with EVs. The delivery efficiency, cellular internalisation pathways and therapeutic effects were evaluated using an in vivo mouse model. RESULTS: SP-A-EVs were robustly internalised into AMs both in vitro and in vivo. Furthermore, our investigation revealed that the toll-like receptor 4-mediated endocytosis pathway was employed for the uptake of SP-A-EVs, significantly delaying their degradation compared with natural EVs, which primarily followed the conventional lysosomal degradation pathway within AMs. In a functional study, we successfully loaded anti-inflammatory microRNA (let-7b) into SP-A-EVs, leading to the suppression of AM activation and the alleviation of lung inflammation induced by lipopolysaccharide. CONCLUSION: These findings underscore the potential of SP-A-EVs as highly effective drug delivery systems for targeted therapeutics in lung-related disorders, capitalising on the strong affinity between AMs and SP-A and the modulation of cellular internalisation.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Kim M, Park S, Lee N, et al. Advanced MicroRNA delivery for lung inflammatory therapy: surfactant protein A controls cellular internalisation and degradation of extracellular vesicles. Thorax. 2025. PMID: 39632081. doi:10.1136/thorax-2024-221793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。